Phase I human trial gives high tolerability/safety grades to potent new XMRV/HIV antiretroviral

Previous in vitro trials found the new chemical entity CMX157 exhibits potent activity against XMRV (20x more than AZT & 800x more than tenofovir) and highly resistant HIV. CMX157 is a modification of tenofovir, an antiretroviral approved for treating HIV & chronic hepatitis B.

More @ ProHealth

Advertisements